Increasing evidence indicates that key aspects of CSC function are dependent on phosphatidylinositol-3 kinase (PI3K) signalling21, while activation of the PI3K/AKT/mammalian target of rapamycin (mTOR) pathway is associated with poor prognosis in GBM patients22. The gene discussed is MTOR; the disease is glioblastoma.